Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive，HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02137083
What this trial is testing

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 22
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)Ended earlyNCT04720664
What this trial is testing

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHormone Receptor Positive Breast Carcinoma
Georgetown University 11
Testing effectiveness (Phase 2)UnknownNCT04571437
What this trial is testing

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
Cairo University 204
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT04448886
What this trial is testing

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Who this might be right for
Invasive Breast CancerMetastatic Breast CancerHR-Positive Breast Cancer+1 more
Ana C Garrido-Castro, MD 110
Not applicableLooking for participantsNCT07613151
What this trial is testing

Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

Who this might be right for
Lobular Breast Carcinoma
Istituto Oncologico Veneto IRCCS 250
Testing effectiveness (Phase 2)Study completedNCT02040857
What this trial is testing

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 162
Testing effectiveness (Phase 2)Study completedNCT03394027
What this trial is testing

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Who this might be right for
Triple Negative Breast CancerEndometrial CancerHormone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT06678269
What this trial is testing

Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerStage IV Breast CancerBreast Cancer+5 more
Memorial Sloan Kettering Cancer Center 28
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Early research (Phase 1)Active Not RecruitingNCT06299124
What this trial is testing

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Who this might be right for
Breast CancerAdvanced Solid Tumor
Regor Pharmaceuticals Inc. 40
Testing effectiveness (Phase 2)Study completedNCT03555877
What this trial is testing

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer Metastatic
GBG Forschungs GmbH 56
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Not applicableNot Yet RecruitingNCT07521202
What this trial is testing

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

Who this might be right for
HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit 257
Early research (Phase 1)Ended earlyNCT04060862
What this trial is testing

Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 20
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Next Page